In a safety net population HPV4 vaccine adherence worsens as BMI increases.

Objectives: Obesity adversely inhibits antibody response to vaccination. Three doses of HPV4 may or may not provide adequate long term protection against HPV 16/18 in obese females. The aim of this study was to determine whether adherence to HPV4 vaccination in a safety net population was reduced with increasing body mass index (BMI).

The influence of free quadrivalent human papillomavirus vaccine (HPV4) on the timely completion of the three dose series.

Objective: Economic incentives can positively influence social determinants to improve the health care of the uninsured and underserved populations. The aim of this study was to determine if free HPV4 vaccine would lead to on-time series completion in our safety net health care system in the US Midwest.

Methods: A nested retrospective cohort study of females receiving HPV4 vaccine between 2006 and 2009 was conducted.

Quantifying clinical HPV4 dose inefficiencies in a safety net population.

Purpose: HPV4 is the most expensive vaccine requiring three appropriately timed doses to provide maximal efficacy against two oncogenic HPV types. The primary purpose of this study is to quantify the use of HPV4 vaccine in a safety net health care system in terms of its inefficiencies.

Methods: A retrospective study of HPV4 dosing from 2006-2009, among females 10-26 years old who sought care in a safety net health care system was conducted to determine dose usage patterns among those at highest risk for cervical cancer.